Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Seeing Both Sides

By Pharmaceutical Processing | January 25, 2013

The late, great Yankees player and coach Billy Martin was not known for holding his tongue. Through many seasons as the Yankees skipper, Martin had more than his fair share of arguments, ejections and fights with umpires and, of course, Yankees owner George Steinbrenner. He certainly had his opinions and always made them known. I remember him in a late 70’s Miller Lite beer commercial. At the time they were really playing up their “Tastes Great. Less Filling.” slogan. In the commercial two of his friends are arguing whether “Tastes Great” or “Less Filling” is more important and turn to Martin for his opinion. “I feel very strongly both ways,” Martin deadpans; completely contrary to his outspoken personality.

I now know how he felt.

Back in December, the 2nd Circuit U.S. Court of Appeals issued its long-awaited decision in the United States vs. Caronia case and ruled that a pharmaceutical sales rep’s conversations with a physician about the off-label use of a drug was protected by the First Amendment.

I have no problem with the free speech aspect of the case. I believe an educated pharmaceutical sales rep should be able to talk to a physician about anything relating to the drug in question.

What concerns me, and here is where I can see both sides, is whether the needs of the patient outweigh safety. In other words, is it ok for a doctor to prescribe a drug for an off-label use because the doctor has seen it work for other conditions?

Doctors (hopefully) become doctors to help people, and at times when indicated drugs don’t work they must feel a great deal of angst prescribing an alternative that is not indicated for treatment. While the FDA does not specifically ban off-label use, these drugs have not been tested by the FDA for their off-label use and their safety for that use cannot be ensured.

“Safety” or “Treatment”? I feel very strongly both ways.  

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE